A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification.

@article{Zhu2018ASO,
  title={A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification.},
  author={Han-ting Zhu and Chunyu Wang and Jingjing Wang and Dawei Chen and Jiaying Deng and Jianyun Deng and J. Fan and H. Badakhshi and Xuesong Huang and Likun Zhang and J. Cai and Shengyue Guo and W. Qian and Y. Nie and Qixiang Li and K. Zhao},
  journal={Journal of thoracic disease},
  year={2018},
  volume={10 9},
  pages={
          5328-5338
        }
}
Background Epidermal growth factor receptor (EGFR) is reportedly overexpressed in most esophageal tumors, but most targeted therapies showed no efficacy in non-selected patients. This study aims at investigating the adaptive cetuximab subset in a cohort of esophageal squamous cell carcinoma (ESCC) patient-derived xenografts (PDXs). Methods A large panel of ESCC PDXs has been established. The copy number, mRNA expression and immunohistochemistry (IHC) of key EGFR pathways have been examined… Expand

References

SHOWING 1-10 OF 39 REFERENCES
Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single‐Arm, Multicenter Phase 2 Study
  • J. Huang, Q. Fan, +6 authors Yiyu Sun
  • Medicine
  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2016
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.
...
1
2
3
4
...